| I muddled around, looking for reasons to buy LEXG in June, wondering why it was available for $16. Then they announced a "tripling" in their long-term MLNM contract. I saw revenues, but not a piece of the pie. The ABGX partnership triggered my buying- a joint discovery alliance. This was followed by an additional discovery pact with ARNA. I don't know whether their "knock-out" agreements with academic centers, i.e, Scripps, Rockefeller, Harvard, Hopkins, Hughes, Stanford, et al, etc., will have any R&D implications, but it does add potential bang-for-the-buck. |
